Celgene in talks to buy Juno Therapeutics – WSJ
Shares of Juno, which has a market value of $5.57 billion, were up 42 percent at $64.59 in extended trading. Chimeric antigen receptor T-cell therapy, or CAR T, harnesses the body’s own immune cells to recognize and attack malignant cells.
Source:: https://finance.yahoo.com/news/celgene-talks-buy-juno-therapeutics-wsj-230014771–finance.html
